Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples

Zhizhen Song,Yueqin Wang,Yue Du,Zhen Zhang,Yongliang Yuan
DOI: https://doi.org/10.1016/j.intimp.2020.106894
IF: 5.714
2020-11-01
International Immunopharmacology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Fibrinogen-like protein 2 (FGL2), a member of the fibrinogen superfamily, has been described to augment immunosuppression in gliomas. However, the precise clinical molecular features and the prognostic relevance of FGL2 in gliomas remain unclear. Therefore, a comprehensive analysis of the role of FGL2 in gliomas would provide insights into the therapeutic implications for this disease.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Totally, 1323 glioma samples with RNA-seq and microarray data from TCGA and CGGA databases were used to clarify the clinical significance and molecular profile of FGL2 in glioma. The findings were further validated through immunohistochemistry (IHC).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>The transcriptional level of FGL2 was positively associated with tumor grade in gliomas, which was confirmed at the protein level through IHC staining. Consistently, FGL2 was significantly enriched in isocitrate dehydrogenase wild-type tumors and the mesenchymal subtype of gliomas. We also demonstrated FGL2 expression correlated with high immune scores and infiltration of immune cell populations, including T cells, macrophages and B cells. Pearson's correlation analysis revealed that FGL2-related genes correlated with inflammatory-immune responses, particularly T cell-mediated immune response. Additionally, FGL2 expression was found tightly associated with immune checkpoints PD-L1 and PD-L2. Clinically, patients with high FGL2 expression exhibited unfavorable overall survival.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>Our results provide the integrative molecular and clinical profiles of FGL2 in gliomas and emphasize the importance of prospective studies on the FGL2-related immune-inflammatory network.</p>
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to understand the molecular and clinical characteristics of fibrinogen - like protein 2 (FGL2) in glioma and its impact on patient prognosis. Specifically, the research aims to: 1. **Clarify the expression pattern of FGL2 in glioma**: By analyzing RNA - seq and microarray data of 1,323 glioma samples from the TCGA and CGGA databases, study the relationship between the transcriptional level of FGL2 and tumor grading, and verify these findings through immunohistochemistry (IHC). 2. **Explore the relationship between FGL2 and glioma molecular subtypes**: Study the expression differences of FGL2 in different molecular subtypes (such as IDH mutation status and mesenchymal subtype) to determine whether FGL2 can be used as a marker for specific subtypes. 3. **Evaluate the relationship between FGL2 and immune cell infiltration**: Use the ESTIMATE and MCP - counter methods to evaluate the relationship between FGL2 expression and immune cell infiltration in the tumor microenvironment, especially the infiltration of T cells, macrophages and B cells. 4. **Analyze FGL2 - related immune - inflammatory responses**: Through gene ontology (GO) enrichment analysis and gene set variation analysis (GSVA), study the functions of FGL2 - related genes, especially their roles in immune - inflammatory responses. 5. **Explore the relationship between FGL2 and immune checkpoint molecules**: Evaluate the correlation between FGL2 expression and the expressions of immune checkpoint molecules such as PD - L1, PD - L2 and CD39 to understand the potential role of FGL2 in immunosuppression. 6. **Evaluate the clinical significance of FGL2**: Through survival analysis, compare the overall survival rates of patients with high FGL2 expression and low FGL2 expression, and explore the potential of FGL2 as a prognostic marker for glioma. In summary, through comprehensive analysis of the molecular and clinical characteristics of FGL2 in glioma, this paper aims to provide new insights and potential therapeutic targets for the treatment of glioma.